GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CellSeed 7776.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

165

+3.13%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CellSeed

Its shares trade on Tokyo Stock Exchange under the ticker 7776.T. It has been listed since 16 March 2010. In the fiscal year to 31 December 2025, it reported revenue of ¥83.7m and a net loss of ¥1.10bn. At that date it held total assets of ¥1.66bn and shareholders' equity of ¥1.27bn.

CellSeed Inc. develops regenerative medicine products. The company is headquartered in Koto-Ku, Tokyo-To. The company went IPO on 2010-03-16. The firm operates in two business segments. The Regenerative Medical Support segment is engaged in the research, development, manufacture and sale of temperature-responsive cell incubators. The Cell Sheet Regeneration Medical segment is involved in the research and development of cell sheet regenerative medical products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
16 Mar 2010
Employees
30

Leadership

Pay as last reported

  • Ms. Setsuko HashimotoPresident, Chief Executive Officer, Representative Director, since 2014
  • Ms. Sachiko EndoIndependent Director
  • Mr. Kenji OedaIndependent Director
  • Mr. Toshio YamaguchiIndependent Director
  • Mr. Itaru HatanakaDirector of Business Management, since 2023

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • CellSeed Inc. develops regenerative medicine products in the Health Care sector.
  • The company operates in two business segments: Regenerative Medical Support and Cell Sheet Regeneration.
  • CellSeed Inc. has a focused workforce of 30 employees in Koto-ku, Tokyo-To.

Weaknesses

  • CellSeed Inc. has only 30 employees, which may limit operational capacity.
  • The company's IPO was in 2010, indicating limited recent market expansion.
  • CellSeed Inc. operates in a niche biotechnology segment with high R&D costs.

Opportunities

  • The Regenerative Medical Support segment offers temperature-responsive cell incubators for medical use.
  • Cell Sheet Regeneration Medical segment targets growing regenerative medicine markets.
  • CellSeed Inc. can leverage its biotechnology expertise in the Health Care industry.

Threats

  • The biotechnology industry faces high regulatory hurdles in Japan.
  • CellSeed Inc. operates in a competitive Health Care sector with established players.
  • The company's small size may hinder access to large-scale funding opportunities.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.